← Leaderboards
Thomas Steven Villani
Visikol, Inc.
$2,079,045
Attributed
$2,079,045
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $844.2K · FY2018–22$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$2,079,045 · 3
By mechanism
R44$1,629,519 · 1
R43$449,526 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Malignant Neoplasms”
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
- Leonard Freedmand · Leidos Biomedical Research, Inc.$108,968,336
- Beverly Hayes · Leidos Biomedical Research, Inc.$98,336,166
- Martha Hering · Westat, Inc.$57,098,843
Research focus
Malignant NeoplasmsHistologicInterestLabelTissuesBaseImagePathologyNeoplasm MetastasisPatient-Focused OutcomesMalignant Breast NeoplasmImproved OutcomeNeoplastic CellPathologistFollow-UpClassificationDigitalDigital PathologyDetectionCessation Of LifeHistopathologyDiagnosisBiopsy SpecimenExcision
Grant awards (4)
Development of a 3D Imaging Diagnostic Tool for the Improved Characterization of Metastatic Melanoma$785,292
R44 · FY2022 · CA · contact PI
Development of a 3D Imaging Diagnostic Tool for the Improved Characterization of Metastatic Melanoma$844,227
R44 · FY2021 · CA · contact PI
Development of a High-Throughput Three-Dimensional H&E Platform for the Characterization of Breast Cancer Biopsies$225,000
R43 · FY2018 · CA · contact PI
Improved Characterization of 3D In Vitro Cell Culture Assays for the Drug Discovery Process$224,526
R43 · FY2018 · GM · contact PI